Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022 16:30 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Participate in Upcoming Investor Conferences
June 01, 2022 08:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 17:00 ET
|
Surface Oncology, Inc.
– SRF388 demonstrated clinical activity in multiple solid tumor types withthree confirmed partial responses across NSCLC, RCC and HCC – – Data support continued evaluation of SRF388 in NSCLC, RCC,...
Surface Oncology to Participate in Upcoming Investor Conferences
May 17, 2022 16:30 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022
May 09, 2022 07:10 ET
|
Surface Oncology, Inc.
– Cash runway extended into 2024 – – Strengthened financial position with achievement of $30 million milestone from GlaxoSmithKline and $21 million raised in the quarter through ATM facility – ...
Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 06, 2022 16:30 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting
April 27, 2022 16:15 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Named one of the 2022 Best Places to Work by Boston Business Journal
April 21, 2022 16:05 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer
April 14, 2022 07:30 ET
|
Surface Oncology, Inc.
Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche Single-arm Phase 2 clinical study evaluating SRF388 as a monotherapy...
Surface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022
April 08, 2022 16:01 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...